Acquired hemophilia A (AHA) is a rare disease resulting from autoantibodies (inhibitors)
against endogenous factor VIII (FVIII) that leads to bleeding, which is often spontaneous and …

Clinical uses of intravenous immunoglobulin | Clinical and Experimental Immunology | Oxford
Academic Skip to Main Content Advertisement intended for healthcare professionals Oxford …

Acquired hemophilia A (AHA), a rare bleeding disorder caused by neutralizing
autoantibodies against coagulation factor VIII (FVIII), occurs in both men and women without …

Background: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by
autoantibodies against coagulation factor VIII and characterized by spontaneous …

Acquired hemophilia A is a rare bleeding disorder caused by autoantibodies to coagulation
FVIII. Bleeding episodes at presentation are spontaneous and severe in most cases. Optimal …

Acquired hemophilia A is a severe bleeding disorder caused by an autoantibody to factor
VIII. Previous reports have focused on referral center patients and it is unclear whether these …

Acquired hemophilia A (AHA) is caused by autoantibodies against factor VIII (FVIII).
Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of …

Acquired hemophilia A (AHA) is an autoimmune disease caused by an autoantibody to
factor VIII. Patients are at risk of severe and fatal hemorrhage until the inhibitor is eradicated …

Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies
directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history …

The revised UKHCDO factor (F) VIII/IX Inhibitor Guidelines (2000) are presented. A schema
is proposed for inhibitor surveillance, which varies according to the severity of the …